anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ALIQOPA (copanlisib) is a kinase inhibitor for intravenous infusion. The active pharmaceutical ingredient is copanlisib dihydrochloride which exists as a non-stoichiometric hydrate and has the molecular formula of C23H28N8O4 2HCl and a molecular weight of 553.45 g/mol. The molecular formula and molecular weight are based on the anhydrous form. The chemical name is 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide dihydrochloride. Copanlisib dihydrochloride has the following structural formula:

ALIQOPA is supplied in single-dose vials as a sterile lyophilized solid for reconstitution and further dilution for intravenous infusion. The product is white to slightly yellowish. After reconstitution, the solution is colorless to slightly yellowish. Each vial contains 60 mg copanlisib free base (equivalent to 69.1 mg copanlisib dihydrochloride). After reconstitution, each mL contains 15 mg copanlisib free base (equivalent to 17.3 mg copanlisib dihydrochloride).

Inactive ingredients: Each vial contains 5.8 mg citric acid anhydrous (might increase to 6.1 mg in case pH correction is necessary), 120 mg mannitol (bulking agent). Citric acid anhydrous acts as a buffering agent and may be used together with sodium hydroxide for pH adjustment.
The present invention provides a communication system for providing automated, electronic communications between at least one health-care provider and a plurality of users of the health-care provider, wherein the communications occur over a communications network through a provider/patient interface, said system comprising:a central server, comprising one server or a logic unit of multiple servers;a provider's service computer,a plurality of users' computers; anda communication network for enabling communication between and among the central server, the provider's service computer, and the plurality of users' computers. In a preferred embodiment, the communication system of the present invention is the Electronic Provider-Patient Interface (the ePPi(TM)). The preferred users of the ePPi system are patients, and the preferred provider is the patient's own doctor or health-care practitioner. At the core of the present invention is a fully automated mechanism for generating a personalized area (patient page) for each user within the doctor's or health-care group's Web site in the ePPi system, and for introducing provider-based content to the system in standardized formats, such as standard administrative and billing codes. Thus, the ePPi system, provides an automated service to patients, through which access to their own doctor is provided over the Internet without additional work for the doctor's office. Moreover, the ePPi system offers patients access to a variety of practice-based services including, appointment requests and updates, prescription refills, online triage, health search information and the like.
This invention provides a skin masking non-woven sheet containing cosmetic material. The non-woven sheet exhibits high sense of transparency in the state that the sheet is impregnated with the cosmetic material and its handling is improved. In this skin masking non-woven sheet containing cosmetic material, one layer or more than one layer of cellulose group-blended fabric layer is used. The one layer or more than one layer of cellulose group- blended fabric layer contains 50 % mass of first cellulose group fabric having a length of fiber of from 20 mm or more to 110 mm or less, and from 8 % or more to 40 % or less by mass of heat sealable fibers, wherein at least a part of the crossing points of construction fibers are heat sealed. The non-woven sheet has a surface density of from 25 g/m2 or more to 48 g/m2 or less as a whole. The non-woven sheet as a whole contains 40.5 % or more by mass of the first cellulose group fiber, and 8 % or more by mass of the heat sealable fibers.
PURPOSE: To produce swine having lessened fats and increased red meat by dosing respectively specific amts. of an exogenous synthesized swine growth hormone, its deriv. or analogous hormones thereof to casturated hog, uncasturated boar and sow. CONSTITUTION: The dosage of the exogenous synthesized swine growth hormone, its deriv. and its analogous hormones (more preferably the recombination growth hormones selected from methionyl AA1-190 and methionyl AA4-190) to the swine having body weights of about 35 to 100kg is started. The dosage is determined at about 0.06 to 0.10mg/kg body weight/day for the casturated hog and about 0.10 to 0.15mg/kg body weight/day for the uncasturated boar.
INTRODUCTION: POLE mutant phenotype in colon adenocarcinomas represents a rare molecular subtype. These tumours are generally responsive to immune-checkpoint inhibition therapy and, therefore, are currently considered as a subtype with good prognosis. We hereby present the first detailed case presentation of a POLE mutant colon adenocarcinoma with useful microscopic features.
CASE REPORT: A 53-year-old male patient's colon adenocarcinoma histologically showed wide variety of growth patterns and massive intra- and peritumoural lymphocytic infiltrate. The majority of the tumour consisted of a high-grade component resembling medullary carcinoma of the colon, while approximately one-third of the tumour was composed of conventional areas exhibiting a tubular pattern. A minority of the tumour was constituted by poorly cohesive rhabdoid cells. Immunohistochemistry was performed, and colorectal origin was proven with CDX-2 and SATB2. Furthermore, proficiency in mismatch repair proteins and SMARCB1 deficiency was observed. The unusually high-grade colon adenocarcinoma, with areas mimicking medullary carcinoma, and generally aggressive morphology raised suspicion of microsatellite instability. The diverse morphology and the SMARCB1 deficiency also raised suspicion of ultramutation caused by POLE alteration. Next-generation sequencing panel confirmed a pathogenetic mutation in POLE exon 9: p.Pro286Arg, c.857C > G.
DISCUSSION: The diverse, high-grade morphology and increased intratumoural lymphoid infiltration should raise suspicion for POLE-mutated adenocarcinoma during everyday histopathological practice. Mismatch repair proficiency results on immunohistochemistry should not determine the final diagnosis, as only a minor percentage of these tumours are MSI. In every case suspicious for POLE-mutated adenocarcinoma, a 500-cancer gene panel should be carried out.
The objective of the current study is to investigate the efficacy and safety of BTI320 compared to placebo in addition to metformin and/or sulfonylureas on glycemic control over 12 weeks in subjects with type 2 diabetes mellitus. This is a randomized, placebo-controlled, double-blind, multi-center study with two treatment arms. Study duration will be approximately 12 weeks. Participants will ingest 4 g BTI320 or matching placebo approximately 10 minutes before starting a meal, 3 times per day, at breakfast, lunch, and dinner. Participants will be instructed not to take the Investigational Medicinal Product with other drugs at the same time. Additional mealtime medication must be taken after consumption of the meal. A nutritionist, dietitian, or study personnel will provide instructions to subjects regarding dietary intake and the need to keep a detailed food record in an online calorie counter and have it entered into an electronic data capture during the study period. In general, subjects will be asked to follow normal meal plans recommended to patients with diabetes. Non-compliance will be defined as taking \<80% or \>120% of Investigational Medicinal Product during any outpatient evaluation period (visit to visit). Subjects who are non-compliant will be replaced to meet the goal of 60 evaluable subjects. Eight study visits will be scheduled after the Screening visit: Baseline (day 0), weeks 3, 6, and 12 (Visits 2, 4, 6, and 8 respectively) for safety and efficacy assessments and Visits 3, 5, 7 and 9 to remove the Continuous Glucose Monitoring System.
Exercise therapy (ET) is considered to be the main conservative treatment for patients with intermittent claudication (IC) and is documented to be effective, especially when supervised. However, wide scale introduction of supervised ET in the Netherlands would lead to a substantial increase of health care costs compared to current practice, while the cost-effectiveness of supervised ET is uncertain. ET follows a pattern of short walking periods that induce discomfort of moderate intensity and short rest periods. The psychological, metabolic, and mechanical alterations that occur during exercise stimulate an adaptive response that ultimately reduces the symptoms. The optimal therapy regimen depends to a large extent on home-based exercises, which require discipline from the patient. Currently, the main prescription for ET for patients with IC in the Netherlands is a single 'go home and walk' advice, without supervision or follow-up. There is no evidence to support the effectiveness of this advice and compliance is low. In studies comparing the 'go home and walk' advice to supervised ET, a large advantage for supervised ET was present. The inadequate use of the main conservative treatment for peripheral arterial disease (PAD) contributes to a gradual progression of this condition, a decrease in quality of life, and an increasing number of vascular interventions. Furthermore, with adequate ET, hypertension, hypercholesterolemia, overweight, and diabetes, if present, is better regulated.
After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
Insect repellants to be applied to the bodies of human beings or animals comprise mixtures of a terpinyl ester of a carboxylic acid and an ointment or toilet cream base.  Esters specified are terpinyl acetate and propionate; or pine oil treated to convert its content of terpinyl alcohol into the acetate may be used. Ointment and toilet cream bases specified are petroleum, lanolin, cold cream, vanishing cream, waxes, soap jellies, and emulsions of fats or fatty acids. Other insect repellants, such as pyrethrum extract, or oils of citronella, cedarwood, chenopodium, lavender, spike, thyme or eucalyptus may also be added.  According to one example the composition contains terpinyl propionate, beeswax, petrolatum or lanolin, and paraffin wax.  Other examples are given in the Specification.  The Specification as open to inspection under Sect. 91 (3) (a) describes also admixtures of the terpinyl esters with diluents or carriers such as light or heavy petroleum oils, alcohols, resins, emulsifying agents such as soaps to permit dilution with water, and toilet powders, and states that the preparations may be used for spraying and for application to clothing, carpets &c. as well as to the human or animal body.  Examples relate to (1) terpinyl acetate dissolved in kerosine; (2) a mixture of terpinyl acetate, kerosene and soap, to be diluted with water; (3) terpinyl acetate dissolved in a kerosene extract of pyrethrum flowers; (4) a lotion containing terpinyl acetate, oil of citronella or oil of cedarwood, oil of chenopodium or of lavender spike, thyme or eucalyptus, and alcohol; and (5) a powder containing terpinyl acetate or propionate, magnesium carbonate, zinc or magnesium stearate, kaolin and talc. This subject-matter does not appear in the Specification as accepted.
Patients are selected according to the eligibility requirements. After obtaining informed consent off-label use and potential risks of sacral neuromodulation, all included patients and next of kin give written informed consent to the study.

At baseline, patients are randomized to one of the two predefined subgroups: either invasive sacral neuromodulation or non-invasive sacral neuromodulation. Clinical symptoms and outcome variables are compared regarding the beginning of non-invasive sacral neuromodulation or the implantation of the tined lead electrode. Patients are closely monitored within 6 months. Treatment success is evaluated in routine clinical check-ups (week 4/8/12 and 24) and via specialized questionnaires and bowel movement diaries. Quality of life is evaluated at baseline and after 12 and 24 weeks of treatment.
This disclosure describes a video-based surgery analytics and quality/skills assessment system. The system takes surgery video as input and generates rich analytics on the surgery. Multiple features may be extracted from the video that describe operation quality and surgeon skills, such as time spent on each step of the surgery, medical device movement trajectory characteristics, and adverse events occurrence such as excessive bleeding. Description of the surgery, related to its difficulty such as patient characteristics, may be also utilized to reflect surgery difficulty. Considering the various extracted features and the surgery description provided by surgeon, a machine learning based model may be trained to assess surgery quality and surgeon skills, by weighing and combining those factors. The system may solve 2 challenges in objective and reliable assessment: differing level of surgery difficulty caused by patient uniqueness and balancing multiple factors that affect quality and skills assessment.
The present inventors have studied an example in order to enhance the differentiation efficiency and maturation of cardiomyocytes derived from stem cells. As a result, it has been confirmed that the differentiation efficiency into stem cell-based cardiomyocytes is improved in an NecroX treatment group, and that further matured cardiomyocytes can be obtained in a short period of time, and the present invention has been completed. Through the treatment of NecroX according to the present invention, cardiomyocytes derived from stem cells have a large size and great thickness compared to a control group, and a strong and dense actin structure is shown. Therefore, it is shown that cardiomyocytes derived from stem cells induced by NecroX treatment can be produced with improved maturation. Accordingly, high efficiency and high purity differentiation of cardiomyocytes derived from stem cells can be induced when NecroX is treated. According to the present invention, NecroX, as a useful material capable of improving the differentiation efficiency and maturation of other differentiated cells, secures differentiation of cardiomyocytes in patient-customized induced pluripotent stem cells, and thus is expected to be helpful in producing a cardiac disease model.
SRT3025 is being developed for the treatment of metabolic diseases. This study is the first administration of SRT3025 in humans and seeks to establish the initial safety, tolerability, and pharmacokinetic (PK) profile of SRT3025 (and any metabolites, if analyzed) before proceeding to future Phase 1 studies or Phase 2 patient studies.

This protocol details a Phase 1, randomized, placebo-controlled, single-blind, dose escalation study to determine the safety, tolerability, and PK profile of SRT3025 in healthy male subjects. The study will be conducted in two parts. In Part 1A, 6 Cohorts of subjects will receive single escalating doses of SRT3025. In Part 1B, an additional one to two cohorts may be enrolled to investigate the effect of a moderate fat/calorie meal on single dose PK endpoints. In Part 2A, up to three cohorts may be enrolled to receive 14-day repeat doses of SRT3025 chosen from the Part 1A safety, tolerability, and PK data. In Part 2B, one to two additional cohorts may receive 14-day repeat doses of SRT3025 in combination with a moderate fat/calorie meal.
OBJECTIVE: The objective of this study was to quantify changes over time in waist circumference (WC) relative to BMI by sex in the Americas (United States, Mexico, Chile, and Peru) and England.
METHODS: Data from adults aged 25 to 64 years between 1997 and 2020 were analyzed, and US data were stratified by race and ethnicity groups. Sex-specific BMI and WC means and obesity and abdominal obesity prevalence were compared between the first and last surveys. Using data from all survey years, secular changes across the BMI and WC distributions were estimated, applying quantile regression models. BMI was added as a predictor of WC to estimate secular changes in WC relative to BMI. Interaction terms were included in all models to evaluate differences by sex.
RESULTS: BMI and WC (except for Peru) showed larger secular increases at the upper-tails of the distributions in both sexes. Increases at the 50th and 75th WC percentiles relative to BMI were more pronounced in women than in men, with larger increases in US non-Hispanic White individuals and in England. In men, increases in WC independent of BMI were most evident in Mexico.
CONCLUSIONS: Disease risk associated with visceral fat is potentially underestimated by national surveillance efforts that quantify only secular changes in BMI.
With improvement of our living standard, patients who suffered from Diabetes become more and more. As the investigators know, Diabetes can induce many ocular diseases leading to vision loss. And according to observations, DME is diagnosed as one main cause of vision loss in the patients with Diabetes.

As the results of many studies conducted previously, anti-VEGF drugs and anti-VEGF treatments show its effect and safety not only in treating AMD, but also in patients with DME. The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The previous clinical trials of KH902 show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF. Due to these positive results, the investigators prepare to conduct a clinical trial to assess the safety and efficacy with intravitreal injection of KH902 in patients with DME.
The invention relates to a pathological image display method, a pathological image display device, electronic equipment and a storage medium, wherein the pathological image display method comprises the following steps: and acquiring first image data, wherein the first image data is a tumor pathology image. And identifying the first image data through the deep learning model to obtain a first image area, wherein the first image area is an image of an area where the tumor main body is located in the first image data. And acquiring a second image area based on the first image data and the first image area, wherein the second image area is an image of a potential cell cluster area outside the area where the tumor main body is located in the first image data. And identifying the second image data through the deep learning model so as to acquire pathological parameters of the cell cluster region. And marking the second image area through different frames based on pathological parameters to obtain a third image area, wherein the third image area is a cell cluster area with different frames. The method can intuitively see different differences of cell clusters around tumors in different frames of different patients.
BACKGROUND: Common complications following kidney transplant include infection, rejection, and malignancy. Multiple masses in a transplanted kidney raise suspicion for malignancy.
CASE PRESENTATION: A 20-year-old female with chronic kidney disease stage 3 T presented with graft tenderness, acute kidney injury, and heterogeneous masses in her transplanted kidney visualized via ultrasound. She was inadequately treated for chlamydia 1 month prior and retested positive upon admission. Initial workup revealed anemia, hyperglycemia, hyperuricemia, and elevated lactate dehydrogenase. Magnetic resonance imaging revealed complex masses of varying sizes in the transplanted kidney. Biopsy grew Streptococcus agalactiae, informing the diagnosis of multiple perinephric abscesses. Additional evaluations for infectious etiology were unremarkable. Her perinephric abscesses resolved with several months of antibiotics.
CONCLUSIONS: Even without a clear source, serious infections may develop in kidney transplant patients who otherwise have concern for malignancy. Chlamydial infections may lead to serious intra-abdominal infections in immunocompromised patients. The inadequately treated chlamydia likely led to polymicrobial ascension of the genitourinary tract that seeded the transplanted kidney. A high index of suspicion for infection is essential in immunosuppressed patients. Biopsy is crucial for a timely diagnosis.
Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
The efficacy of vilazodone hydrochloride as a treatment for major depressive disorder was demonstrated in four multicenter, randomized, double-blind, placebo-controlled studies in adult (18 to 70 years of age) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for MDD. Three 8-week studies evaluated the efficacy of vilazodone hydrochloride 40 mg (Studies 1 to 3) and one 10-week study (Study 4) evaluated the efficacy of vilazodone hydrochloride 20 mg and 40 mg (see Table 5). In these studies, patients were randomized to either 20 mg or 40 mg, or placebo once daily with food. Patients were either titrated over 1 week to a dose of 20 mg daily or over 2 weeks to a dose of 40 mg once daily of vilazodone hydrochloride with food. Vilazodone hydrochloride was superior to placebo in the improvement of depressive symptoms as measured by the change from baseline to endpoint visit in the Montgomery-Asberg Depression Rating Scale (MADRS) total score for both doses. The MADRS is a ten-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the MADRS range from 0 to 60, with higher scores indicating more severe depression. Clinical Global Impression - Severity (CGI-S) was evaluated in Studies 3 and 4. Vilazodone hydrochloride 20 mg and 40 mg demonstrated superiority over placebo as measured by improvement in CGI-S score. 

Baseline demographics information were generally similar across all treatment groups. Examination of population subgroups based on age (there were few patients over 65), gender and race did not reveal any clear evidence of differential responsiveness.
Plants have emerged as an alternative expression system for producing target proteins. However, the ability of plants to glycosylate proteins can be a significant limitation for those proteins, which do not require N- glycosylation. For example, Plasmodium falciparum proteins, or A chain of human factor XIII, or all bacterial originated antigens, for example, the protective antigen (PA) of Bacillus anthracis do not require N- glycosylation, but aberrantly glycosylated in any eukaryotic expression system. This invention relates to materials and methods for producing recombinant proteins of interest in plants in a non-N-glycosylated, native-like, with no amino acid change in the NxS/T site, by co-expression of target proteins of interest with Endo-I3-N-acetylglucosaminidase H (Endo H). Materials and methods for in vivo de-glycosylation of recombinant N-glycosylated proteins by co-expression with Endo H in plants, using a transient expression system are described. A method of expressing active Endo H in plants also is provided.